Please Wait.....
Report
Atopic Dermatitis Market By Drug Class (Biologics, Calcineurin Inhibitors, PDE-4 Inhibitor, Corticosteroids, Others), By Mode Of Administration (Topical, Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-09-01 I 293 Pages I Allied Market Research
The global atopic dermatitis market was valued at $5,333.37 million in 2021, and is projected to reach $22,594.44 million by 2031, registering a CAGR of 15.1% from 2022 to 2031. Atopic dermatitis is a chronic, pruritic inflammatory skin condition (see image below) that typically affects the face (cheeks), neck, arms, and legs but usually spares the groin and axillary regions. Atopic dermatitis usually starts in early infancy, but also affects a substantial number of adults. Atopic dermatitis is commonly associated with elevated levels of immunoglobulin E (IgE). Atopic dermatitis is the first disease to present in a series of allergic diseases including food allergy, asthma, and allergic rhinitis, which has given rise to the atopic march theory, which suggests that atopic dermatitis is a part of a progression that may lead to subsequent allergic disease at other epithelial barrier surfaces.
The primary symptom of atopic dermatitis is dry, itchy skin that often turns into a red rash during flare-ups. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle. It's hard to fight the physical and psychological elements that drive this cycle. Scratching feels good at the time but can lead to more inflammation and even skin infections. Atopic dermatitis has different symptoms depending on a person's age. The atopic dermatitis market is expected to experience significant market growth during the forecast period as there has been a rapid development of novel pipeline drugs. Likewise, rise in demand for new biologics and product approvals are also predicted to enhance the atopic dermatitis market growth. Furthermore, the favorable reimbursement policies in emerging countries and high prevalence of atopic dermatitis are projected to drive the market growth rate. Moreover, increase in awareness regarding the availability of treatments for the disease and various initiatives undertaken by governments to provide better and more affordable treatment are expected to influence the atopic dermatitis market growth globally. In addition, the rapid technological advancement and the rise in funding along with increase in government support for research and development are likely to create various new opportunities for the market growth during the forecast period.
However, the easy availability of expensive treatment and poor reimbursement policies in the developing regions across the globe are expected to act as major restraints toward the growth of the atopic dermatitis market, whereas the allergic reactions of off-label therapies and patent expiry of products can challenge the growth of the target market during the forecast period. The atopic dermatitis market is segmented on the basis of drug class, route of administration, distribution channel, and region. By drug class, the market is classified into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, and others. By indication, the market is classified into topical, injectable, and oral. By end user, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
North America accounted for the largest market share in the atopic dermatitis market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of atopic dermatitis, high treatment awareness among the patient population across the U.S., well-established healthcare infrastructure, and early adoption of novel medications. For instance, as per the 2022 National Eczema Association, an estimated 16.5 million U.S. adults (7.3%) have atopic dermatitis that initially began at more than two years of age, with nearly 40% affected by moderate or severe disease.
The report provides a comprehensive analysis of the key players that operate in the global atopic dermatitis market. The key companies profiled in the report include AbbVie Inc., Arcutis Biotherapeutics, Inc., Asana Biosciences, Inc., Astellas Pharma, Inc., Bayer AG, Inc., Bristol-Myers Squibb Inc., Dermavant Sciences, Inc., Eli Lilly and Company, Inc., Galderma, Inc., Incyte Corporation, Inc., Leo Pharma, Inc., Novartis AG, Otsuka Pharmaceuticals Co., Ltd., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Inc., and Viatris, Inc.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atopic dermatitis market analysis from 2021 to 2031 to identify the prevailing atopic dermatitis market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the atopic dermatitis market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global atopic dermatitis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- PDE-4 Inhibitor
- Corticosteroids
- Others
- Biologics
- Calcineurin Inhibitors
- Type
- Tacrolimus
- Pimecrolimus
By Mode Of Administration
- Topical
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Sanofi SA
- Novartis International AG
- Bristol-Myers Squibb
- Bayer AG
- AbbVie Inc.
- Pfizer Inc.
- Astellas Pharma Inc.
- Regeneron Pharmaceuticals Inc.
- Arcutis Biotherapeutics
- Asana Biosciences
- Dermavant
- Eli Lilly
- Galderma
- Incyte
- Viatris
- Leo Pharma
- Otsuka Holdings Co.,Ltd
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ATOPIC DERMATITIS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Biologics
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Calcineurin Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Calcineurin Inhibitors Atopic Dermatitis Market by Type
4.3.4.1 Tacrolimus Market size and forecast, by region
4.3.4.2 Pimecrolimus Market size and forecast, by region
4.4 PDE-4 Inhibitor
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Corticosteroids
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Topical
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Injectable
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Oral
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ATOPIC DERMATITIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.2.3 North America Market size and forecast, by Mode Of Administration
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Mode Of Administration
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Mode Of Administration
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Mode Of Administration
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.3.3 Europe Market size and forecast, by Mode Of Administration
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Mode Of Administration
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Mode Of Administration
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Mode Of Administration
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Mode Of Administration
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Mode Of Administration
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Mode Of Administration
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Mode Of Administration
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Mode Of Administration
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Mode Of Administration
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Mode Of Administration
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Mode Of Administration
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Mode Of Administration
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Mode Of Administration
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Calcineurin Inhibitors Atopic Dermatitis Market by Type
7.5.3 LAMEA Market size and forecast, by Mode Of Administration
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Mode Of Administration
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Mode Of Administration
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Mode Of Administration
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Mode Of Administration
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Sanofi SA
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Novartis International AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bristol-Myers Squibb
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bayer AG
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 AbbVie Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Pfizer Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Astellas Pharma Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Regeneron Pharmaceuticals Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Arcutis Biotherapeutics
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Asana Biosciences
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Dermavant
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Eli Lilly
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Galderma
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Incyte
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Viatris
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Leo Pharma
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Otsuka Holdings Co.,Ltd
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. ATOPIC DERMATITIS MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ATOPIC DERMATITIS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ATOPIC DERMATITIS MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ATOPIC DERMATITIS MARKET FOR CALCINEURIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 7. ATOPIC DERMATITIS MARKET, FOR TACROLIMUS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. ATOPIC DERMATITIS MARKET, FOR PIMECROLIMUS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. ATOPIC DERMATITIS MARKET, FOR PDE-4 INHIBITOR, BY REGION, 2021-2031 ($MILLION)
TABLE 10. ATOPIC DERMATITIS MARKET FOR PDE-4 INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. ATOPIC DERMATITIS MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. ATOPIC DERMATITIS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. ATOPIC DERMATITIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. ATOPIC DERMATITIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 16. ATOPIC DERMATITIS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
TABLE 17. ATOPIC DERMATITIS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. ATOPIC DERMATITIS MARKET, FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
TABLE 19. ATOPIC DERMATITIS MARKET FOR INJECTABLE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. ATOPIC DERMATITIS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 21. ATOPIC DERMATITIS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 23. ATOPIC DERMATITIS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. ATOPIC DERMATITIS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. ATOPIC DERMATITIS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. ATOPIC DERMATITIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. ATOPIC DERMATITIS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 28. ATOPIC DERMATITIS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. ATOPIC DERMATITIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 36. U.S. ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 37. U.S. ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. CANADA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 40. CANADA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. MEXICO ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 43. MEXICO ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 45. EUROPE CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 47. EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. EUROPE ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. GERMANY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 51. GERMANY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. FRANCE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 54. FRANCE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. UK ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 57. UK ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. ITALY ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 60. ITALY ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. SPAIN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 63. SPAIN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. JAPAN ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 74. JAPAN ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. CHINA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 77. CHINA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. INDIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. INDIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 83. INDIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 91. LAMEA CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 93. LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94. LAMEA ATOPIC DERMATITIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 96. BRAZIL ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 97. BRAZIL ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY MODE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA ATOPIC DERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.SANOFI SA: COMPANY SNAPSHOT
TABLE 108.SANOFI SA: OPERATING SEGMENTS
TABLE 109.SANOFI SA: PRODUCT PORTFOLIO
TABLE 110.SANOFI SA: NET SALES,
TABLE 111.SANOFI SA: KEY STRATERGIES
TABLE 112.NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 113.NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 114.NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 115.NOVARTIS INTERNATIONAL AG: NET SALES,
TABLE 116.NOVARTIS INTERNATIONAL AG: KEY STRATERGIES
TABLE 117.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 118.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 119.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 120.BRISTOL-MYERS SQUIBB: NET SALES,
TABLE 121.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
TABLE 122.BAYER AG: COMPANY SNAPSHOT
TABLE 123.BAYER AG: OPERATING SEGMENTS
TABLE 124.BAYER AG: PRODUCT PORTFOLIO
TABLE 125.BAYER AG: NET SALES,
TABLE 126.BAYER AG: KEY STRATERGIES
TABLE 127.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 128.ABBVIE INC.: OPERATING SEGMENTS
TABLE 129.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 130.ABBVIE INC.: NET SALES,
TABLE 131.ABBVIE INC.: KEY STRATERGIES
TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
TABLE 133.PFIZER INC.: OPERATING SEGMENTS
TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 135.PFIZER INC.: NET SALES,
TABLE 136.PFIZER INC.: KEY STRATERGIES
TABLE 137.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 138.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 139.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 140.ASTELLAS PHARMA INC.: NET SALES,
TABLE 141.ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 142.REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 143.REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 144.REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 145.REGENERON PHARMACEUTICALS INC.: NET SALES,
TABLE 146.REGENERON PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 147.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
TABLE 148.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
TABLE 149.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
TABLE 150.ARCUTIS BIOTHERAPEUTICS: NET SALES,
TABLE 151.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
TABLE 152.ASANA BIOSCIENCES: COMPANY SNAPSHOT
TABLE 153.ASANA BIOSCIENCES: OPERATING SEGMENTS
TABLE 154.ASANA BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 155.ASANA BIOSCIENCES: NET SALES,
TABLE 156.ASANA BIOSCIENCES: KEY STRATERGIES
TABLE 157.DERMAVANT: COMPANY SNAPSHOT
TABLE 158.DERMAVANT: OPERATING SEGMENTS
TABLE 159.DERMAVANT: PRODUCT PORTFOLIO
TABLE 160.DERMAVANT: NET SALES,
TABLE 161.DERMAVANT: KEY STRATERGIES
TABLE 162.ELI LILLY: COMPANY SNAPSHOT
TABLE 163.ELI LILLY: OPERATING SEGMENTS
TABLE 164.ELI LILLY: PRODUCT PORTFOLIO
TABLE 165.ELI LILLY: NET SALES,
TABLE 166.ELI LILLY: KEY STRATERGIES
TABLE 167.GALDERMA: COMPANY SNAPSHOT
TABLE 168.GALDERMA: OPERATING SEGMENTS
TABLE 169.GALDERMA: PRODUCT PORTFOLIO
TABLE 170.GALDERMA: NET SALES,
TABLE 171.GALDERMA: KEY STRATERGIES
TABLE 172.INCYTE: COMPANY SNAPSHOT
TABLE 173.INCYTE: OPERATING SEGMENTS
TABLE 174.INCYTE: PRODUCT PORTFOLIO
TABLE 175.INCYTE: NET SALES,
TABLE 176.INCYTE: KEY STRATERGIES
TABLE 177.VIATRIS: COMPANY SNAPSHOT
TABLE 178.VIATRIS: OPERATING SEGMENTS
TABLE 179.VIATRIS: PRODUCT PORTFOLIO
TABLE 180.VIATRIS: NET SALES,
TABLE 181.VIATRIS: KEY STRATERGIES
TABLE 182.LEO PHARMA: COMPANY SNAPSHOT
TABLE 183.LEO PHARMA: OPERATING SEGMENTS
TABLE 184.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 185.LEO PHARMA: NET SALES,
TABLE 186.LEO PHARMA: KEY STRATERGIES
TABLE 187.OTSUKA HOLDINGS CO.,LTD: COMPANY SNAPSHOT
TABLE 188.OTSUKA HOLDINGS CO.,LTD: OPERATING SEGMENTS
TABLE 189.OTSUKA HOLDINGS CO.,LTD: PRODUCT PORTFOLIO
TABLE 190.OTSUKA HOLDINGS CO.,LTD: NET SALES,
TABLE 191.OTSUKA HOLDINGS CO.,LTD: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.ATOPIC DERMATITIS MARKET SEGMENTATION
FIGURE 2.ATOPIC DERMATITIS MARKET,2021-2031
FIGURE 3.ATOPIC DERMATITIS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ATOPIC DERMATITIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.ATOPIC DERMATITIS MARKET,BY DRUG CLASS,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF BIOLOGICS ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITORS ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PDE-4 INHIBITOR ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 18.ATOPIC DERMATITIS MARKET,BY MODE OF ADMINISTRATION,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TOPICAL ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INJECTABLE ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ORAL ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 22.ATOPIC DERMATITIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ATOPIC DERMATITIS MARKET,2021-2031(%)
FIGURE 26.ATOPIC DERMATITIS MARKET BY REGION,2021
FIGURE 27.U.S. ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 28.CANADA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 29.MEXICO ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 30.GERMANY ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 31.FRANCE ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 32.UK ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 33.ITALY ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 34.SPAIN ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 35.REST OF EUROPE ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 37.CHINA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 38.AUSTRALIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 39.INDIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH KOREA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 41.REST OF ASIA-PACIFIC ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 42.BRAZIL ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 43.SAUDI ARABIA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 44.SOUTH AFRICA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 45.REST OF LAMEA ATOPIC DERMATITIS MARKET,2021-2031($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50.COMPETITIVE DASHBOARD
FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 52.SANOFI SA.: NET SALES ,($MILLION)
FIGURE 53.NOVARTIS INTERNATIONAL AG.: NET SALES ,($MILLION)
FIGURE 54.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
FIGURE 55.BAYER AG.: NET SALES ,($MILLION)
FIGURE 56.ABBVIE INC..: NET SALES ,($MILLION)
FIGURE 57.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 58.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
FIGURE 59.REGENERON PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 60.ARCUTIS BIOTHERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 61.ASANA BIOSCIENCES.: NET SALES ,($MILLION)
FIGURE 62.DERMAVANT.: NET SALES ,($MILLION)
FIGURE 63.ELI LILLY.: NET SALES ,($MILLION)
FIGURE 64.GALDERMA.: NET SALES ,($MILLION)
FIGURE 65.INCYTE.: NET SALES ,($MILLION)
FIGURE 66.VIATRIS.: NET SALES ,($MILLION)
FIGURE 67.LEO PHARMA.: NET SALES ,($MILLION)
FIGURE 68.OTSUKA HOLDINGS CO.,LTD.: NET SALES ,($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security